Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ERþ/HER2-breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the toxicity of this pairing is unknown. We report preliminary results on the use of this combination. Methods and Materials: Records of patients treated with palbociclib at our institution from 2015 to 2018 were retrospectively reviewed. Patients who received RT for symptomatic metastases concurrently or within 14 days of palbociclib were included. Local treatment effect was assessed by clinical examination and subsequent computed tomography/magnetic resonance imaging. Toxicity was graded based on Common Terminology Criteria for Adverse Events version 5.0. Results: A total of 16 women received palliative RT in close temporal proximity to palbociclib administration. Four patients received palbociclib before RT (25.0%), 5 concurrently (31.3%), and 7 after RT (43.8%). The median interval from closest palbociclib use to RT was 5 days (range, 0-14). The following sites were irradiated in decreasing order of frequency: bone (11 axial skeleton [9 vertebra and 2 other]; 4 pelvis; 3 extremity), brain (4: 3 whole brain RT and 1 stereotactic radiosurgery), and mediastinum (1). The median and mean follow-up time is 14.7 and 17.6 months (range, 1.7-38.2). Pain relief was achieved in all patients. No radiographic local failure was noted in the 13 patients with evaluable follow-up imaging. Leukopenia, neutropenia, and thrombocytopenia were seen in 4 (25.0%), 5 (31.3%), and 1 (6.3%) patient before RT. After RT, 5 (31.3%), 1 (6.3%), and 3 (18.8%) patients were leukopenic, neutropenic, and thrombocytopenic, respectively. All but 2 (grade 2) hematologic toxicities were grade 1.
Introduction
Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved for the treatment of metastatic ERþ/HER2-breast cancer. [1] [2] [3] The interaction of cyclin D with CDK4 and CDK6 results in the hyperphosphorylation of the retinoblastoma gene product, which ultimately leads to progression from G1 to the S phase of the cell cycle. 4 Palbociclib-induced inhibition of CDK4/6 prevents cell cycle progression and thus halts uncontrolled cancer cell division.
Preclinical data suggest palbociclib may augment the therapeutic effect of radiation therapy (RT) via multiple methods. [5] [6] [7] Despite this potential benefit, clinicians seldom use this combination out of fear that RT may exacerbate palbociclib toxicity, particularly neutropenia and leukopenia. We report the preliminary results of patients who received RT while being treated with palbociclib for metastatic breast cancer.
Methods and Materials
With institutional review board approval, we retrospectively reviewed records of all patients who were treated with palbociclib at Rush University Medical Center from 2015 to 2018. The starting palbociclib dose was 125 mg daily from day 1 to 21 in association with either fulvestrant 500 mg every 28 days or letrozole 2.5 mg daily. Patients who received RT for symptomatic metastasis concurrently or within 14 days of palbociclib administration (mean half-life of 26 hours 8 The following sites were treated in order of frequency: bone (11 axial skeleton [9 vertebra; 2 other]; 4 pelvis; 3 extremity), brain (4: 3 WBRT and 1 fSRS), and mediastinum (1). Sixteen of 18 osseous sites received conventional RT (range, 30-37.5 Gy/10-15 fractions fxn), Abbreviation: RT Z radiation therapy.
whereas 2 received stereotactic body RT (18 Gy/1 fxn and 30 Gy/3 fxn). For brain, WBRT ranged from 30 to 35 Gy in 10 to 14 fxn and fSRS brain dose was 25 Gy in 5 fxn.
The patient treated to the mediastinum received 36 Gy in 18 fxn. Table 2 shows full RT treatment characteristics for each patient.
Treatment outcomes and toxicity
At the most recent follow-up, 12 patients are still living. The median and mean time from RT to last known follow-up or death is 14.7 and 17.6 months (range, 1.7-38.2), respectively. Median pre-RT pain was 8 (range, 6-10). Pain relief was achieved in all patients (median: 2 [range, 0-3]). No radiographic local failure was noted in the 13 patients with evaluable follow-up imaging.
The combination of RT and palbociclib was well-tolerated. Grade 1 fatigue, dermatitis, and nausea were noted in 5, 3, and 1 patient, respectively. One patient who underwent WBRT developed grade 1 headache. No acute or late grade 2 or higher cutaneous, neurologic, or gastrointestinal toxicities were noted. Table 3 shows hematologic parameters before and after RT. The median time interval from blood draw and RT was 12 days (0-40) and 8 days (1-47) for pre-and postvalues, respectively. The median pre-and post-RT white blood cell (normal, 4.0-10.0 k/uL), neutrophil (normal, 1.84-7.8 K/uL), and platelet count (normal, 150-399 K/uL) was 5.12 and 4.8, 2.83 and 3.19, and 250 and 210, respectively. Leukopenia, neutropenia, and thrombocytopenia were seen in 4 (25.0%), 5 (31.3%), and 1 (6.3%) patients before RT. After RT, 5 (31.3%; 4 new [3 grade 1 and 1 grade 2]), 1 (6.3%; grade 2), and 3 (18.8%; grade 1) patients were leukopenic, neutropenic, and thrombocytopenic, respectively.
No patients developed infections after RT. All but 2 (grade 2) hematologic toxicities were grade 1. There was no difference in toxicities based on palbociclib-RT sequencing or by irradiated site.
Discussion
Palbociclib is the first CDK 4/6 inhibitor approved for metastatic ERþ/HER2-breast cancer based on the promising results of the PALOMA studies. Preclinical evidence suggests that palbociclib may act synergistically with RT. Palbociclib-induced inhibition of CDK4/6 prevents cell cycle progression to the more radioresistant S phase. Moreover, palbociclib can act as a DNA double-strand break repair inhibitor, 7 thus amplifying the anticancer effect of RT.
The most frequently seen toxicity with palbociclib is hematologic, which can also occur after irradiation. Many patients with metastatic breast cancer become Abbreviations: 3D-CRT Z 3-dimensional conformal radiation therapy; C Z cervical; fSRS Z fractionated stereotactic radiosurgery; Fxn Z fraction; IMRT Z intensity modulated radiation therapy; L Z lumbar; LR Z local recurrence; RT Z radiation therapy; SBRT Z stereotactic body radiation therapy; T Z thoracic; WBRT Z whole brain radiation therapy. symptomatic and need RT; however, the lack of published clinical toxicity data results in physician reluctance to administer RT to patients receiving palbociclib.
Therefore, we examined the safety and efficacy of concomitant palbociclib and RT in 16 patients with breast cancer with symptomatic metastases. With a median follow-up time of 14.7 months, we report no significant increase in acute or late toxicities, particularly hematologic, with this novel combination as compared to reports of palbociclib alone. Additionally, no differences were seen when assessing toxicity based on irradiated site (axial vs pelvis vs other) or palbociclib-RT relation (pre-, post-, and concurrent; Table 3 ). Sustained pain relief was achieved in all patients, and no local failures were seen in the evaluable patients.
After exhaustive literature review, we found only 1 published study investigating this combination in humans. Consistent with our findings, Hans et al 9 also report no increase in toxicity in 5 patients treated with palbociclib and RT; however, their study does not report follow-up time, local control, or toxicities grouped by irradiated site or proximity of RT and palbociclib administration.
Preclinical studies of palbociclib and RT in nonbreast cancer also seem to be promising. Two studies 6,10 of palbociclib and RT in glioblastoma cell lines showed increased tumor cell apoptosis with the combination compared to monotherapy. Another study showed that palbociclib sensitized both tumor cell lines and autochthonous mouse tumors to radiation in medulloblastoma. 5 Similar results are seen in hepatocellular carcinoma, 7 cholangiocarcinoma, and non-small cell lung cancer 11 cell lines. Jointly, these studies suggest that palbociclib may be a promising drug to increase the therapeutic ratio of RT.
Conclusions
The use of RT in patients with metastatic breast cancer receiving palbociclib resulted in minimal grade 1 to 2 and no grade 3þ toxicities. This preliminary work suggests that RT in this patient population is safe and feasible.
Subsequent studies with longer follow-up are needed to confirm these results and investigate further use of palbociclib with RT.
